ATE451103T1 - Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält - Google Patents

Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält

Info

Publication number
ATE451103T1
ATE451103T1 AT04768663T AT04768663T ATE451103T1 AT E451103 T1 ATE451103 T1 AT E451103T1 AT 04768663 T AT04768663 T AT 04768663T AT 04768663 T AT04768663 T AT 04768663T AT E451103 T1 ATE451103 T1 AT E451103T1
Authority
AT
Austria
Prior art keywords
rosuvastatin
treatment
composition
containing candesartan
atherosclerosis containing
Prior art date
Application number
AT04768663T
Other languages
English (en)
Inventor
Jay Mehta
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Application granted granted Critical
Publication of ATE451103T1 publication Critical patent/ATE451103T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
AT04768663T 2003-09-26 2004-09-22 Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält ATE451103T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322552.1A GB0322552D0 (en) 2003-09-26 2003-09-26 Therapeutic treatment
PCT/GB2004/004120 WO2005030215A2 (en) 2003-09-26 2004-09-22 Therapeutic treatment

Publications (1)

Publication Number Publication Date
ATE451103T1 true ATE451103T1 (de) 2009-12-15

Family

ID=29286881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768663T ATE451103T1 (de) 2003-09-26 2004-09-22 Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält

Country Status (28)

Country Link
US (2) US7932263B2 (de)
EP (1) EP1673091B1 (de)
JP (1) JP4841433B2 (de)
KR (1) KR101129767B1 (de)
CN (1) CN100515421C (de)
AT (1) ATE451103T1 (de)
AU (1) AU2004275567B2 (de)
BR (1) BRPI0414724A (de)
CA (1) CA2540102C (de)
CY (1) CY1109814T1 (de)
DE (1) DE602004024555D1 (de)
DK (1) DK1673091T3 (de)
ES (1) ES2336450T3 (de)
GB (1) GB0322552D0 (de)
HR (1) HRP20100080T1 (de)
IL (1) IL174536A (de)
IS (1) IS2729B (de)
MX (1) MXPA06003353A (de)
NO (1) NO335813B1 (de)
NZ (1) NZ546162A (de)
PL (1) PL1673091T3 (de)
PT (1) PT1673091E (de)
RU (1) RU2358737C2 (de)
SG (1) SG145773A1 (de)
SI (1) SI1673091T1 (de)
UA (1) UA90249C2 (de)
WO (1) WO2005030215A2 (de)
ZA (1) ZA200602433B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
EP2483401B1 (de) * 2009-09-29 2017-06-21 Butamax (TM) Advanced Biofuels LLC Wirtszellen mit erhöhter hefeproduktion
US20120239131A1 (en) * 2011-03-15 2012-09-20 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysmal tissue
HRP20170263T2 (hr) * 2011-12-09 2018-12-28 Ims Medical D.O.O. LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE
CN103479627A (zh) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
KR101771766B1 (ko) 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
CN109996545A (zh) * 2016-11-15 2019-07-09 株式会社Lg化学 用于治疗2型糖尿病和糖尿病性血脂异常的药物复合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US6004989A (en) 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
EP2253327A1 (de) 1996-04-05 2010-11-24 Takeda Pharmaceutical Company Limited Pharmazeutische Zusammensetzung enthaltend eine Angiotensin-II antagonistisch wirkende Verbindung in Kombination mit einer anderen Verbindung
PT930076E (pt) * 1996-07-15 2005-01-31 Sankyo Co Composicoes medicinais
JPH1081633A (ja) 1996-07-16 1998-03-31 Sankyo Co Ltd 医薬組成物
IL133957A0 (en) 1997-08-29 2001-04-30 Pfizer Prod Inc Combination therapy comprising amlodipine and a statin compound
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2368049A1 (en) 1999-04-13 2000-10-19 Basf Aktiengesellschaft Integrin receptor ligands
BR0013704A (pt) 1999-08-30 2002-05-07 Aventis Pharma Gmbh Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
AU782386C (en) 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AR030414A1 (es) 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
MXPA02010090A (es) * 2000-04-12 2003-02-12 Novartis Ag Combinacion de al menos dos compuestos seleccionados de los grupos de un antagonista del receptor at-1 o un inhibidor ace o un inhibidor de la hmg-co-a reductasa.
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2002145770A (ja) * 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
EP1314425A4 (de) * 2000-08-30 2004-06-02 Sankyo Co Medizinische zusammenstellung zur prophylaxe und behandlung von herzversagen
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
PT1355644E (pt) * 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
DE60220269T2 (de) 2001-01-26 2008-01-17 Schering Corp. Kombinationen eines hemmers der sterolabsorption und eines kardiovaskulären wirkstoffes zur behandlung von kardiovaskulären indikationen
US20030053950A1 (en) * 2001-04-18 2003-03-20 Mcgill University Individualization of therapy with hyperlipidemia agents
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
EP1620437B1 (de) * 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
JP2005126338A (ja) 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20060078615A1 (en) 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin

Also Published As

Publication number Publication date
US20070275989A1 (en) 2007-11-29
SG145773A1 (en) 2008-09-29
SI1673091T1 (sl) 2010-03-31
NO20061744L (no) 2006-06-22
PT1673091E (pt) 2010-02-15
IL174536A (en) 2010-12-30
AU2004275567B2 (en) 2008-01-10
HRP20100080T1 (hr) 2010-04-30
KR20060108623A (ko) 2006-10-18
DK1673091T3 (da) 2010-03-22
ES2336450T3 (es) 2010-04-13
NZ546162A (en) 2008-11-28
EP1673091A2 (de) 2006-06-28
BRPI0414724A (pt) 2006-11-21
JP4841433B2 (ja) 2011-12-21
NO335813B1 (no) 2015-02-23
WO2005030215A2 (en) 2005-04-07
IS2729B (is) 2011-04-15
IS8421A (is) 2006-04-21
MXPA06003353A (es) 2006-06-08
JP2007506720A (ja) 2007-03-22
CA2540102A1 (en) 2005-04-07
GB0322552D0 (en) 2003-10-29
KR101129767B1 (ko) 2012-03-26
AU2004275567A1 (en) 2005-04-07
CA2540102C (en) 2012-07-24
CN1886136A (zh) 2006-12-27
RU2006113366A (ru) 2007-11-10
DE602004024555D1 (de) 2010-01-21
US7932263B2 (en) 2011-04-26
HK1090553A1 (en) 2006-12-29
PL1673091T3 (pl) 2010-04-30
UA90249C2 (uk) 2010-04-26
CN100515421C (zh) 2009-07-22
IL174536A0 (en) 2008-04-13
RU2358737C2 (ru) 2009-06-20
WO2005030215A3 (en) 2005-06-02
CY1109814T1 (el) 2014-09-10
US20110046119A1 (en) 2011-02-24
EP1673091B1 (de) 2009-12-09
ZA200602433B (en) 2007-06-27

Similar Documents

Publication Publication Date Title
CY1109814T1 (el) Ενας συνδυασμος που περιεχει candesartan και rosuvastatin για τη θεραπευτικη αντιμετωπιση της αρτηριοσκληρυνσης
DE60137329D1 (de) Zusammensetzungen zur behandlung von diabetes die einen dp iv-inhibitoren und einen andere antidiabetikum enthalten
DE602004007808D1 (de) Neue gamma secretase inhibitoren
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
SE0203752D0 (sv) New compounds
DE50214540D1 (de) Stanz bei der behandlung von wunden
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
DE60221627D1 (de) Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
WO2004018431A3 (en) Novel phenanthridines
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
EP1474139A4 (de) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer zur behandlung von diabetes, adipositas und dyslipidämie
DE60133921D1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
DE60139466D1 (de) Behandlung von diabetes
DE60134009D1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
ATE502631T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
TW200503707A (en) Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease
DE50302552D1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE60111571D1 (de) Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1673091

Country of ref document: EP